A Pharmaceutical Strategy for Europe

Bianca Marmandiu a fait une demande de Accès à l'information à Parlement européen

Automatic anti-spam measures are in place for this older request. Please let us know if a further response is expected or if you are having trouble responding.

La demande est réussie.

Bianca Marmandiu

Dear European Parliament,

Referring to Regulation (EC) No 1049/2001 on public access to EU documents and to the 'Aarhus Convention' I would herewith like to ask for access to the following information:

All documents that include the text of the compromise amendments with regards to the committee votes on ‘A Pharmaceutical Strategy for Europe’ A9-0317/2021 2021/2013(INI) Committee on Legal Affairs, roll-call votes of 13.07.2021. Specifically:
Compromise Amendment 1;
Compromise Amendment 2;
Compromise Amendment 3;
Compromise Amendment 4;
Compromise Amendment 5;
Compromise Amendment 6;
Compromise Amendment 7;
Compromise Amendment 8;
Compromise Amendment 9;
Compromise Amendment 10;
Compromise Amendment 11;
Compromise Amendment 12;
Compromise Amendment 13;
Compromise Amendment 14 and the documents regarding the split amendments;
Amendment 21 Part 1;
Amendment 21 Part 2.

Thank you in advance.

Yours faithfully,
Bianca Marmandiu

Parlement européen

Our reference: 2022- 0440

Dear Ms Marmandiu,

The European Parliament hereby acknowledges receipt of your message, which
was registered on 06/04/2022.

All applications for public access to documents are treated in compliance
with Regulation (EC) No 1049/2001 of 30 May 2001 regarding public access
to European Parliament, Council and Commission documents.

In accordance with the above-mentioned Regulation, your application will
be handled within 15 working days upon registration of your request.

Your personal data will be processed in accordance with Regulation (EU)
2018/1725 of 23 October 2018 on the protection of natural persons with
regard to the processing of personal data by the Union institutions,
bodies, offices and agencies and on the free movement of such data. A
detailed privacy statement is available [1]here.

The European Parliament reserves the right to ask for additional
information regarding your identity in order to verify compliance with
Regulation (EC) No 1049/2001 and the European Parliament’s implementing
measures.

Your attention is drawn to the fact that you have lodged your application
via the AsktheEU.org website, which is a private website not officially
related to the European Parliament. Therefore, the European Parliament
cannot be held accountable for any technical issues or problems linked to
the use of this system.

In addition, please note that any personal data that you provide by using
AsktheEU.org website may be disclosed to the general public and visible on
this private website. The European Parliament cannot be held responsible
for such disclosure. Should you need to communicate directly to Parliament
any personal data and would like to avoid public disclosure, you may do so
from your private email address by using the following functional mailbox
address: AccesDocs(at)europarl.europa.eu

Best regards,

TRANSPARENCY UNIT
European Parliament
Directorate-General for the Presidency
Directorate-General for Interinstitutional Affairs and Legislative
Coordination
[2][European Parliament request email]
[3]www.europarl.europa.eu/RegistreWeb

References

Visible links
1. https://www.europarl.europa.eu/RegistreW...
2. mailto:[European Parliament request email]
3. http://www.europarl.europa.eu/RegistreWeb

AccesDocs, Parlement européen

3 Attachments

 

Our reference: 2022-0440

 

 

Dear Ms Marmandiu,

 

Your application for access to "All documents that include the text of the
compromise amendments with regards to the committee votes on ‘A
Pharmaceutical Strategy for Europe’ A9-0317/2021 2021/2013(INI) Committee
on Legal Affairs, roll-call votes of 13.07.2021. Specifically:

Compromise Amendment 1;

Compromise Amendment 2;

Compromise Amendment 3;

Compromise Amendment 4;

Compromise Amendment 5;

Compromise Amendment 6;

Compromise Amendment 7;

Compromise Amendment 8;

Compromise Amendment 9;

Compromise Amendment 10;

Compromise Amendment 11;

Compromise Amendment 12;

Compromise Amendment 13;

Compromise Amendment 14 and the documents regarding the split amendments;

Amendment 21 Part 1;

Amendment 21 Part 2. " has been registered on 07/04/2022 with the
reference 2022-0440.

 

Please find attached the voting list for the vote taken in JURI on 12 July
2021 on ‘A Pharmaceutical Strategy for Europe’ (2021/2013(INI)).

The document includes:

            the text of all CAs;

            indication of the split vote on Article 21 as well as the
text corresponding to the two parts.

 

Please note that there are no split amendments related to CA14 and that
split votes on CAs are not allowed.

Splits votes on other amendments (as well as the corresponding texts)
appear in the attached document. 

Also, please note that the final text of the opinion may differ from the
aggregated text of the CAs, following the verification by DLA.

 

Please see attached the document with the final compromise amendments,
that were put to vote on the DEVE opinion to the draft general budget of
the European Union for the financial year 2022 (2021/0227(BUD))

 

The request in fact mentions "documents that include the text of the split
amendments". However, there were no split AMs in this vote.

 

Please follow the link for the DEVE Amendments:

[1]https://devenet.in.ep.europa.eu/home/wel...

 

On this basis Parliament considers your request handled and the file
closed. Please do not hesitate to submit a new request should you identify
specific Parliament documents for which you would like to request public
access.

 

 

Kind regards,

 

 

[2]cid:image001.png@01D58B31.E2CF1C20 TRANSPARENCY UNIT

 
European Parliament
Directorate-General for the
Presidency
Directorate for Interinstitutional
Affairs and Legislative Coordination
[3][email address]
[4]www.europarl.europa.eu/RegistreWeb

 

 

 

References

Visible links
1. https://devenet.in.ep.europa.eu/home/wel...
3. mailto:[email address]
4. http://www.europarl.europa.eu/RegistreWeb